<DOC>
	<DOC>NCT00191633</DOC>
	<brief_summary>The purpose of this study is to assess whether changes in the symptoms of ADHD show a relationship with changes in functioning in children with ADHD treated with atomoxetine over a 3-month period.</brief_summary>
	<brief_title>Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Patients must have ADHD, be outpatients, who are at least 6 years of age and not more than 11 years 8 months of age at Visit 1 so that all testing will be completed before the child reaches age 12. Patients must have moderately severe symptoms of ADHD. Patients must be able to swallow study drug capsules. Patients must not have Bipolar disorder, psychosis, autism, Asperger's syndrome, pervasive developmental disorder, or seizure disorder. Patients must not have taken atomoxetine prior to starting the study.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>